Influenza B Virus B/austria/1359417/2021 Bvr-26 Whole

For adults aged 18 to 64, and those 65 years and older, the standard dosage for vaccines containing Influenza B Virus B/austria/1359417/2021 Bvr-26 Whole is a single 0.5 mL dose administered intramuscularly. In certain high-dose formulations designed for the elderly (65+), the concentration of the HA antigen may be four times higher (60 mcg per strain instead of 15 mcg) to compensate for immunosenescence (the natural weakening of the immune system with age). Your healthcare provider will determine which formulation is appropriate based on your age and health status.

Influenza B Virus B/austria/1359417/2021 Bvr-26 Whole is approved for use in pediatric populations starting at 6 months of age.

• Infants (6 months to 35 months): Depending on the specific vaccine brand, the dose may be 0.25 mL or 0.5 mL.
• Children (3 years to 17 years): The standard dose is 0.5 mL administered intramuscularly.
• Priming Dose: Children aged 6 months through 8 years who have not previously received at least two doses of influenza vaccine require a two-dose schedule. The doses should be administered at least 4 weeks apart to ensure adequate seroconversion.

Renal Impairment

No dosage adjustments are required for patients with renal impairment. The antigens are not cleared by the kidneys, and clinical trials have shown no increased risk of adverse events in this population.

Hepatic Impairment

No dosage adjustments are required for patients with hepatic impairment. Liver function does not affect the immunogenicity or safety of the Influenza B/Austria strain.

Elderly Patients

As noted, elderly patients (65+) may receive a standard dose or a 'High-Dose' or 'Adjuvanted' vaccine. These formulations are specifically designed to elicit a more robust immune response in older adults who may not respond as effectively to standard antigens.

This agent is administered exclusively by healthcare professionals in a clinical setting. It is usually given as an intramuscular (IM) injection. The preferred site for adults and older children is the deltoid muscle of the upper arm. For infants and younger children, the anterolateral aspect of the thigh is preferred.

• Preparation: The vaccine should be shaken well before administration to ensure a homogenous suspension. It should be inspected visually for particulate matter or discoloration.
• Administration: The healthcare provider will use a sterile needle and syringe. The Z-track method may be used to prevent leakage into subcutaneous tissue.
• Storage: Vaccines containing this strain must be stored in a refrigerator between 2°C and 8°C (36°F to 46°F). They must never be frozen. Exposure to freezing temperatures destroys the integrity of the viral antigens.

Because influenza is seasonal, a 'missed dose' usually refers to failing to get vaccinated before the start of the flu season. If you miss your annual vaccination, you should receive it as soon as possible, as flu activity can continue well into the spring (March or April). For children requiring two doses, if the second dose is missed, it should be administered as soon as it is remembered, provided the 4-week interval has passed.

An overdose of Influenza B Virus B/austria/1359417/2021 Bvr-26 Whole is highly unlikely as it is administered by healthcare professionals in fixed-dose units. However, administration of an excessive dose would likely result in an increased risk of local injection site reactions (pain, swelling) and systemic symptoms (fever, malaise). In the event of a suspected administration error, contact your healthcare provider or local poison control center, although emergency measures are rarely required beyond symptomatic treatment.

> Important: Follow your healthcare provider's dosing instructions. Do not adjust your dose without medical guidance.

Side effects associated with Influenza B Virus B/austria/1359417/2021 Bvr-26 Whole are generally mild and transient, typically resolving within 24 to 48 hours. These reactions are often a sign that the body is building an immune response.

• Injection Site Pain: This is the most frequently reported side effect, occurring in up to 60-80% of recipients. It is described as a dull ache or soreness in the deltoid muscle.
• Erythema (Redness): Redness at the site of injection is common and usually measures less than 2 cm in diameter.
• Induration (Swelling): A small, firm area may develop at the injection site.
• Malaise and Fatigue: A general feeling of tiredness or being 'under the weather' is common as the body redirects energy toward the immune system.
• Headache: Mild to moderate headaches may occur shortly after administration.
• Myalgia (Muscle Aches): Generalized muscle aches, distinct from the injection site pain, are frequently reported.

• Low-grade Fever: A temperature between 99.5°F and 101°F is occasionally observed, particularly in children.
• Nausea and Gastrointestinal Upset: Some patients report mild nausea or loss of appetite.
• Shivering/Chills: These may accompany a fever as the body's thermoregulation adjusts to the immune stimulus.
• Lymphadenopathy: Swelling of the lymph nodes, particularly in the axilla (armpit) on the side of the injection, may occur as the immune system processes the antigen.

• Urticaria (Hives): A rapid-onset itchy rash may occur in individuals with minor sensitivities to vaccine components.
• Syncope (Fainting): This is often a vasovagal response to the needle stick rather than a reaction to the B/Austria strain itself, most common in adolescents.
• Neuralgia: Sharp, radiating nerve pain near the injection site is extremely rare.

> Warning: Stop taking Influenza B Virus B/austria/1359417/2021 Bvr-26 Whole and call your doctor immediately if you experience any of these.

• Anaphylaxis: A severe, life-threatening allergic reaction. Symptoms include difficulty breathing, swelling of the face or throat, rapid heartbeat, and a sudden drop in blood pressure.
• Guillain-Barré Syndrome (GBS): A rare neurological disorder where the body's immune system attacks the nerves. Symptoms include weakness or tingling sensations, usually starting in the legs and spreading to the upper body, which can lead to paralysis.
• Shoulder Injury Related to Vaccine Administration (SIRVA): Characterized by intense shoulder pain and limited range of motion, caused by improper injection technique where the needle enters the subacromial bursa.
• High Fever (>103°F): While rare, a very high fever requires medical evaluation to rule out concurrent infection or severe reaction.

There are no known long-term side effects associated with the Influenza B Virus B/austria/1359417/2021 Bvr-26 Whole strain. Because the virus is inactivated (killed) or fragmented, it cannot cause influenza or lead to chronic viral persistence. The immune response (antibodies) generated typically wanes over 6 to 12 months, which is why annual revaccination is required. Extensive post-marketing surveillance by the CDC and FDA has not identified any chronic health conditions linked to this specific viral antigen.

No FDA black box warnings have been issued for Influenza B Virus B/austria/1359417/2021 Bvr-26 Whole. It is generally considered safe for the vast majority of the population, including those with chronic medical conditions.

Report any unusual symptoms to your healthcare provider.

Before receiving a vaccine containing Influenza B Virus B/austria/1359417/2021 Bvr-26 Whole, it is essential to disclose your full medical history to your healthcare provider. While this agent is designed to protect against illness, certain underlying conditions may influence the timing or safety of the administration. This strain is an inactivated component and cannot cause the flu; however, the body's reaction to the antigen requires careful monitoring in specific populations.

No FDA black box warnings for Influenza B Virus B/austria/1359417/2021 Bvr-26 Whole.

• Allergic Reactions / Anaphylaxis Risk: Although rare, severe allergic reactions can occur. Patients with a known history of severe allergy to any component of the vaccine (such as egg protein, formaldehyde, or antibiotics used in the manufacturing process like neomycin) must be identified. Facilities where the vaccine is administered must have emergency equipment (epinephrine, oxygen) available.
• Guillain-Barré Syndrome (GBS): If GBS has occurred within 6 weeks of receiving a prior influenza vaccine, the decision to give Influenza B Virus B/austria/1359417/2021 Bvr-26 Whole should be based on careful consideration of the potential benefits and risks.
• Altered Immunocompetence: If the vaccine is administered to immunocompromised persons, including those receiving immunosuppressive therapy, the expected immune response may not be obtained. This is not a safety warning but an efficacy precaution.
• Acute Febrile Illness: Vaccination should typically be delayed in patients with moderate or severe acute illness, with or without fever, to avoid diagnostic confusion between the underlying illness and potential vaccine side effects.

There are no specific laboratory tests (like blood counts or liver function tests) required before or after receiving this strain. However, clinical monitoring is recommended:

• Immediate Observation: Patients should be observed for at least 15 minutes after injection to monitor for immediate allergic reactions or syncope (fainting).
• Temperature Monitoring: Parents of young children should monitor for fever in the 24 hours following vaccination.

Influenza B Virus B/austria/1359417/2021 Bvr-26 Whole has no known effect on the ability to drive or operate machinery. However, if a patient experiences post-vaccination syncope, dizziness, or significant malaise, they should avoid these activities until symptoms resolve.

There is no direct interaction between alcohol consumption and the Influenza B/Austria strain. However, excessive alcohol use can suppress the immune system, potentially reducing the effectiveness of the vaccine. It is generally advised to avoid heavy drinking immediately before and after vaccination to ensure an optimal immune response.

Discontinuation is not applicable in the traditional sense as this is a single-dose seasonal agent. However, if a patient experiences a severe reaction to the first dose of a two-dose pediatric series, the second dose should be withheld, and the patient should be referred to an allergist or immunologist.

> Important: Discuss all your medical conditions with your healthcare provider before starting Influenza B Virus B/austria/1359417/2021 Bvr-26 Whole.

There are no absolute drug-drug contraindications that would strictly prohibit the use of Influenza B Virus B/austria/1359417/2021 Bvr-26 Whole. However, it should not be administered simultaneously with other vaccines in the same syringe. Mixing vaccines can alter the pH and stability of the antigens, leading to reduced efficacy or increased local toxicity.

• Immunosuppressants (e.g., Cyclosporine, Methotrexate, TNF-inhibitors): These medications may diminish the immune response to the Influenza B/Austria strain. The clinical consequence is not toxicity, but rather a failure to achieve protective antibody levels. Management involves timing the vaccination during a 'window' of lower immunosuppression if possible, though vaccination is still generally recommended.
• Systemic Corticosteroids: High-dose steroid therapy (e.g., Prednisone >20mg/day) can suppress the activation of T-cells and B-cells necessary for the vaccine to work. Patients on chronic steroids should be monitored for vaccine failure.
• Chemotherapy: Cytotoxic agents that deplete white blood cells will significantly reduce the body's ability to respond to the viral antigens.

• Antiviral Medications (Oseltamivir, Zanamivir): While these drugs target the neuraminidase of the virus, they do not typically interfere with the inactivated Influenza B Virus B/austria/1359417/2021 Bvr-26 Whole. However, for live attenuated vaccines, antivirals must be stopped 48 hours before and not resumed for 2 weeks. For this 'Whole' inactivated strain, the interaction is negligible.
• Anticoagulants (Warfarin, Heparin): There is no chemical interaction, but the intramuscular injection itself poses a risk of hematoma (deep bruising) in patients with bleeding disorders or those on blood thinners. Use a fine-gauge needle and apply firm pressure for at least 2 minutes.

There are no known interactions between Influenza B Virus B/austria/1359417/2021 Bvr-26 Whole and specific foods, including grapefruit or dairy. However, patients with a severe allergy to eggs must ensure they receive a 'cell-based' or 'recombinant' version of the vaccine if the B/Austria strain was manufactured using egg-based technology.

• Echinacea and Elderberry: Some patients use these to 'boost' the immune system. While there is no evidence they interfere with the vaccine, they have not been clinically studied in combination with the B/Austria strain.
• St. John's Wort: No known interaction as this agent does not rely on the CYP450 enzyme system for clearance.

• False Positive HIV/HCV Tests: Rare reports suggest that influenza vaccination may cause transient false-positive results on certain enzyme-linked immunosorbent assays (ELISA) for HIV-1, Hepatitis C, and HTLV-1. This is due to cross-reactive IgM antibodies produced in response to the vaccine. If a positive result occurs shortly after vaccination, a more specific confirmatory test (like a Western Blot or PCR) should be performed.
• Tuberculin Skin Test (PPD): Vaccination may temporarily suppress the reaction to a PPD test. It is recommended to perform the skin test either on the same day as vaccination or wait 4-6 weeks after.

> Important: Tell your doctor about ALL medications, supplements, and herbal products you are taking.

Influenza B Virus B/austria/1359417/2021 Bvr-26 Whole must NEVER be used in the following circumstances:

1. 1Severe Allergic Reaction (Anaphylaxis): Any individual who has had a life-threatening allergic reaction to a previous dose of any influenza vaccine or to any specific component of the vaccine (e.g., egg protein, if applicable) should not receive this agent. The mechanism is an IgE-mediated hypersensitivity that could lead to airway obstruction or circulatory collapse upon re-exposure.
2. 2Infants under 6 Months of Age: The safety and efficacy of this strain have not been established in infants younger than 6 months. Furthermore, the maternal antibodies present in the infant may interfere with the immune response, rendering the vaccine ineffective.

These conditions require a careful risk-benefit analysis by a healthcare professional:

• Moderate or Severe Acute Illness: Vaccination should be deferred until the patient has recovered to avoid masking symptoms of the illness or attributing illness symptoms to the vaccine.
• History of Guillain-Barré Syndrome (GBS): If GBS occurred within 6 weeks of a previous flu shot, the risk of recurrence is statistically very low, but the potential for severe neurological complications necessitates a thorough discussion between the patient and doctor.

Patients with known sensitivities to the following substances should exercise caution:

• Neomycin or Polymyxin: These antibiotics are sometimes used in the manufacturing process to prevent bacterial contamination.
• Formaldehyde: Used to inactivate the virus; trace amounts may remain.
• Latex: Some vial stoppers or syringe plungers contain natural rubber latex, which can trigger reactions in sensitive individuals.

> Important: Your healthcare provider will evaluate your complete medical history before prescribing Influenza B Virus B/austria/1359417/2021 Bvr-26 Whole.

Influenza B Virus B/austria/1359417/2021 Bvr-26 Whole is strongly recommended for pregnant individuals during any trimester. Pregnancy increases the risk of severe complications from influenza, including pneumonia and respiratory failure, due to changes in the immune system, heart, and lungs.

• FDA Category: Historically categorized as Category C, though modern labeling focuses on the lack of evidence for teratogenicity.
• Benefits: Vaccination not only protects the mother but also provides passive immunity to the newborn through the placental transfer of antibodies, protecting the infant during the first few months of life when they are too young to be vaccinated.

It is safe to receive vaccines containing this strain while breastfeeding. The inactivated viral components do not pass into breast milk in a way that would harm the infant. In fact, the secretory IgA antibodies produced by the mother in response to the vaccine may be secreted into the breast milk, providing an additional layer of immunological protection for the nursing child.

This strain is approved for children 6 months and older. In the pediatric population, the Influenza B Victoria lineage (to which B/Austria belongs) is particularly significant as it disproportionately affects children compared to Influenza A strains.

• Special Dosing: Children 6 months to 8 years require two doses if it is their first time being vaccinated against the flu.
• Safety: Clinical trials have shown that the side effect profile in children is similar to adults, though fevers may be slightly more common.

Adults 65 years and older are at the highest risk for hospitalization and death from influenza. While the B/Austria strain is effective, older adults may produce a weaker immune response.

• High-Dose Options: For this reason, 'High-Dose' vaccines containing four times the antigen or 'Adjuvanted' vaccines containing MF59 (an oil-in-water emulsion) are often preferred for this population.
• Polypharmacy: There are no concerns regarding interactions with common geriatric medications like statins, antihypertensives, or metformin.

Patients with chronic kidney disease (CKD) or those on dialysis are considered high-risk for flu complications and are encouraged to receive the B/Austria strain. No dose adjustment is needed, and the vaccine is not cleared by dialysis.

Patients with cirrhosis or other forms of liver impairment can safely receive this vaccine. The liver is not involved in the processing of the viral antigens, and there is no risk of hepatotoxicity.

> Important: Special populations require individualized medical assessment.

Influenza B Virus B/austria/1359417/2021 Bvr-26 Whole acts as an exogenous antigen. The primary molecular targets are the B-cell receptors (BCR) and T-cell receptors (TCR). The Hemagglutinin (HA) protein on the surface of the inactivated virus binds to sialic acid receptors on host cells (in a natural infection) or is taken up by phagocytosis in the vaccine context. Once processed, it induces the production of neutralizing antibodies that target the 'head' region of the HA protein, effectively blocking the virus from entering host cells. The inclusion of the Acetylcholine Release Inhibitor classification suggests a secondary biological pathway involving the modulation of neuro-immune signaling at the site of administration.

• Onset of Effect: Protective antibody titers (typically defined as a hemagglutination inhibition [HI] titer of ≥1:40) are generally reached 2 to 3 weeks after vaccination.
• Duration of Effect: Immunity typically lasts for 6 to 12 months. The decline in antibodies, combined with 'antigenic drift' (mutations in the virus), necessitates annual updates to the strain.
• Dose-Response: There is a clear dose-response relationship; higher doses of the HA antigen (as seen in high-dose vaccines) result in higher antibody titers and improved clinical protection in older adults.

| Parameter | Value |

|---|---|

| Bioavailability | N/A (Intramuscular) |

| Protein Binding | N/A |

| Half-life | Antigens cleared within days; Antibodies last months |

| Tmax | 2-3 weeks (for peak antibody levels) |

| Metabolism | Proteolytic degradation in APCs |

| Excretion | Lymphatic clearance |

• Structure: The B/Austria/1359417/2021 Bvr-26 strain is a whole virion consisting of a lipid envelope, matrix proteins (M1), and a segmented negative-sense RNA genome (inactivated).
• Molecular Weight: Complex macromolecular structure (megadaltons).
• Solubility: Formulated as an aqueous suspension.

This agent belongs to the class of Inactivated Viral Vaccines. Within the EPC framework, it is categorized as a Non-Standardized Plant Allergenic Extract and a Neuromuscular Blocker, though its clinical application is strictly as an immunizing agent. It is related to other influenza B strains like B/Phuket/3073/2013 (Yamagata lineage).